JR-171 Phase I/II study  Ver sion 6.00  
Protocol number: JR-171-101  12 November 2021  
 1 / 68 
  
Clinical Study Protocol  
Phase I/II study of JR-171 in patients with 
mucopolysaccharidosis type I  
 
Protocol Number:  JR-171- 101 
Version Number: ver. 6.00  
Compound: JR-171 
Study Phase: Phase I/ II 
 
Sponsor: JCR Pharmaceuticals Co., Ltd.  
3-19 Kasuga-cho Ashiya, Hyogo, Japan 659-0021  
 
National Clinical Trial (NCT) Identified Number/IND Number:  
[STUDY_ID_REMOVED]  
 
Approval Date:  12 November 2021  
 
Sponsor Responsible:  
 
Clinical Study Manager, Development Division  
2-4 Kasuga-cho Ashiya, Hyogo, Japan 659-0021  
 
CONFIDENTIALITY STATEMENT : This document includes information only shared with 
parties immediately involved in the study. When you publish or disclose to any third party the 
content of this document, prior consent must be obtained from JCR Pharmaceuticals Co., Ltd . 
This study will be conducted according to the principles of Good Clinical Practice as described 
in International Conference on Harmonisation guidelines, including the archiving of essential 
documents (CPMP/ICH/135/95).  

JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 2 / 68 
 Signature [CONTACT_3264]:  
 
 
I have read Protocol JR-171-101. I agree to conduct the study as detailed in this 
protocol and in compliance with Declaration of Helsinki, International Conference on 
Harmonisation Good Clinical Practices (ICH-GCP) and all applicable regulatory 
requirements and guidelines.  
 
 
 
 
 
Pr
incipal Investigator   
 Date  
 
 
 
 
 
 
As 
the sponsor representative, I confirm that JCR Pharmaceuticals Co., Ltd. will 
comply with all sponsor obligations as detailed in all applicable regulations and 
guidelines. I will ensure that the Principal Investigator [INVESTIGATOR_434058].  
 
 
 
 
 
Clinic
al Study Manager  
JCR Pharmaceuticals Co., Ltd.   
 Date  
 
 
 
 
 
 
Me
dical Monitor Name [CONTACT_9352] [CONTACT_17055].  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 3 / 68 
 Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  
Ver. 1.00.000 (Original Protocol)  [ADDRESS_550111] 2021  
Ver. 6.00  12 November 2021  
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 4 / 68 
 Table of Contents  
1. Protocol Summary  ......................................................................................................................  7 
1.1 Synopsis  ...............................................................................................................................  7 
1.2 Schema  ............................................................................................................................... 10 
1.3 Schedule of Activities  .......................................................................................................... 12 
2. Introduction  ............................................................................................................................... 16 
2.1 Study Rationale1) ................................................................................................................ 16 
2.2 Background  ......................................................................................................................... 17 
2.3 Benefit/Risk Assessment  .................................................................................................... 17 
2.3.1  Known Potential Risks  ................................................................................................ 17 
2.3.2  Known Potential Benefits  ............................................................................................ 17 
2.3.3  Assessment of Potential Risks and Benefits  .............................................................. 17 
3. Objectives and Endpoints ......................................................................................................... 18 
4. Study Design  ............................................................................................................................ 20 
4.1 Overall Design  .................................................................................................................... 20 
4.2 Scientific Rationale for Study Design  ................................................................................. 21 
4.3 Justification for Dose  .......................................................................................................... 22 
4.4 End of Study Definition  ....................................................................................................... 23 
5. Study Population  ...................................................................................................................... 23 
5.1 Inclusion Criteria  ................................................................................................................. 23 
5.2 Exclusion Criteria  ................................................................................................................ 24 
5.3 Lifestyle Considerations  ..................................................................................................... 24 
5.4 Screen Failures  ................................................................................................................... 24 
5.5 Strategies for Recruitment and Retention  .......................................................................... 25 
6. Study Intervention  .................................................................................................................... 26 
6.1 Study Interventions Administered  ....................................................................................... 26 
6.1.1  Composition  ................................................................................................................ 28 
6.2 Preparation/Handling/Storage/Accountability  ..................................................................... [ADDRESS_550112] Storage and Stability  ..................................................................................... 29 
6.2.3  Preparation  ................................................................................................................. 29 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................................. 29 
6.4 Study Intervention Compliance  .......................................................................................... 29 
6.5 Concomitant Medication/Therapy  ....................................................................................... 29 
6.5.1  Prohibited Concomitant Medications/Therapi[INVESTIGATOR_014]  ......................................................... [ADDRESS_550113] Discontinuation /Withdrawal  .................... [ADDRESS_550114] Discontinuation/Withdrawal from the Study  .......................................................... [ADDRESS_550115] to Follow- up ................................................................................................................ 33 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 5 / 68 
 8. Study Assessments and Procedures  ....................................................................................... 33 
8.1 Demographic and Other Baseline Characteristics  ............................................................. 33 
8.2 Safety Assessments  ........................................................................................................... 34 
8.2.1  Pregnancy Testing (Female Subjects of Childbearing Potential Only) ....................... 34 
8.2.2  Administration Information  .......................................................................................... 35 
8.2.3  Vital Signs  ................................................................................................................... 35 
8.2.4  Laboratory Tests  ......................................................................................................... 35 
8.2.5  Antibodies  ................................................................................................................... 35 
8.2.6  12-lead Electrocardiogram .......................................................................................... 36 
8.2.7  Concomitant Medication/Therapy  ............................................................................... 36 
8.3 Adverse Events and Serious Adverse Events  .................................................................... 36 
8.3.1  Time Period and Frequency for Collecting AE and SAE Information  ......................... 36 
8.3.2  Method of Detecting AEs and SAEs  ........................................................................... 37 
8.3.3  Follow-up of AEs and SAEs  ........................................................................................ 37 
8.3.4  Regulatory Reporting Requirements for SAEs  ........................................................... 37 
8.3.5  Pregnancy (Female Subjects and Subject’s Female Co-partners of Childbearing 
Potential Only)  ............................................................................................................ [ADDRESS_550116]  ..................................................................................................... 41 
8.5.9  Other Clinical Findings Related to Neurocognitive and Behavioral Changes  ............ 41 
8.5.10  BVMT-R and HVLT-R  ..................................................................................................41  
8.5.11  T.O.V.A.  ....................................................................................................................... 42 
8.5.12  PedsQL-FIM  ................................................................................................................ 42 
8.5.13  Status of Cross-Reactive Immunologic Material (CRIM) ............................................ 42 
9. Statistical Considerations  ......................................................................................................... 42 
9.1 Statistical Hypotheses  ........................................................................................................ 42 
9.2 Sample Size Determination  ................................................................................................ 43 
9.3 Populations for Analyses  .................................................................................................... 43 
9.4 Statistical Analyses  ............................................................................................................. 43 
9.4.1  General Considerations  .............................................................................................. 43 
9.4.2  Demographic and Other Baseline Characteristics  ..................................................... 44 
9.4.3  Safety Analyses  .......................................................................................................... 44 
9.4.4  Analysis of the Pharmacokinetic endpoints  ................................................................ 45 
9.4.5  Analyses of the Exploratory Endpoints  ....................................................................... 45 
9.4.6  Subgroup Analyses  ..................................................................................................... 46 
9.5 Interim Analyses  ................................................................................................................. 47 
9.6 Independent Data Safety Monitoring Committee (IDSMC)  ................................................ 47 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 6 / 68 
 10. Supporting Documentation and Operational Considerations  .................................................. 48 
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ............................. [ADDRESS_550117] Policy  ............................................................................................ 55 
10.1.21  Additional considerations  ............................................................................................ 55 
10.2 Appendix 2: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-
up, and Reporting  ............................................................................................................... 56 
10.2.1  Definition of AE  ........................................................................................................... 56 
10.2.2  Definition of Clinically Relevant Changes in Laboratory Assessments  ...................... 57 
10.2.3  Definition of SAE  ......................................................................................................... 57 
10.2.4  Recording and Follow-Up of AE and/or SAE  .............................................................. 57 
10.2.5  Reporting of SAEs  ...................................................................................................... 59 
10.3 Appendix 3: Abbreviations  ..................................................................................................61  
10.4 Appendix 4: Protocol Amendment History  .......................................................................... 63 
11. References  ............................................................................................................................... 67 
 
 
Statement of Compliance  
The study will be carried out in accordance with the following: the Declaration of Helsinki-
Ethical Principles for Medical Research Involving Human Subjects- which was adopted by [CONTACT_941] 
18th World Medical Association General Assembly and its amendments; ICH-GCP and related 
regulations/regional requirements; this protocol.  
In the [LOCATION_002] (US), the US Code of Federal Regulations (CFR) is applicable to clinical 
studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56 and 21 CFR Part 312).  
The protocol, informed consent form(s) (ICF(s)), and all subject materials will be submitted to 
the Institutional Review Board (IRB) for review and approval. Approval of both the protocol and 
the ICF(s) must be obtained before any subject is enrolled. Any amendment to the protocol will 
require review and approval by [CONTACT_3484]. In 
addition, all changes to the ICF will be IRB-approved; a determination will be made regarding 
whether a new consent needs to be obtained from patient or the patient’s legally acceptable 
representative.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 8 / 68 
  Assessment of the other clinical findings 
r
elated to neurocognitive and behavioral 
changes  
 Changes in outcome of the Brief 
Visuospatial Memory Test-Revised 
(BVMT-R) and Hopkins Verbal Learning 
Test-Revised (HVLT- R) from baseline* to 
Week  13 (Part 2 only)  
 Changes in outcome of the Test of 
Variables of Attention (T.O.V.A.) from 
baseline* to Week  13 (Part  2 only)  
 Changes in outcome of the Pediatric 
Quality of Life Inventory Family Impact 
Module (PedsQL-FIM) from baseline* to 
Week  13 (Part 2 only)  
* Use the data determined in the screening period as the  baseline data. 
Study Population:  
Male or female MPS I patients (18  years old or older in Part  1, and 2  years or older (any age 
in Japan and Brazil) in Part  2). 
 
Inclusion Criteria  
1. A patient aged 18  years or older in Part 1 or 2  years or older (any age in Japan and Brazil) 
in Part 2, at the time of informed consent.  
2. A patient from whom written informed consent can be obtained. If the patient is aged under 
18 years (20  years in case of Japan) at the time of assent or willingness to participate in 
the study cannot be confirmed due to MPS I-related intellectual disability, informed 
permission from the patient’s legally acceptable representative ( e.g., his/her parents or 
guardians) needs to be obtained instead of his/her consent. Even in this case, written 
informed consent should be obtained from the patient, wherever possible.  
3. A patient diagnosed with MPS I based on any one of the following criteria:  
 Activity of the IDUA enzyme below 10% of the lower reference level in leucocytes or 
cultured skin fibroblasts, AND increased age-related urinary levels of 
glycosaminoglycans (GAGs) (before enzyme replacement therapy (ERT)).  
 Activity of the IDUA enzyme below 10% of the lower reference level in leucocytes or 
cultured skin fibroblasts, AND presence of one pathogenic mutation in each of the 
alleles of the IDUA gene.  
 Increased age-related urinary levels of GAGs (before ERT), AND presence of one 
pathogenic mutation in each of the alleles of the IDUA gene.  
4. A patient diagnosed as having mild or no MPS I-related intellectual disability (able to report 
their own subjective symptoms) by [CONTACT_458] [INVESTIGATOR_249585] (Part  1 
only).  
5. A patient who has received laronidase continuously for at least 12  weeks and has received 
laronidase at a stable dosage for the 2  weeks immediately before the initial administration 
of JR-171 (except for a laronidase naïve patient or a patient who has previously been 
treated by [CONTACT_59512] (HSCT)).  
6. Female patient or male patient whose co-partner is of child-bearing potential agrees to 
use a medically accepted, highly effective method of contraception, such as spermatocidal 
gel plus condom, an intrauterine device or oral contraceptives until one month after the 
final administration.  
Exclusion Criteria  
1. A patient who has received gene therapy treatment.  
2. A patient who, in the opi[INVESTIGATOR_434059], cannot 
undergo lumbar puncture, including those who have a difficulty in taking position for lumbar 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 9 / [ADDRESS_550118] within the 12 months prior to 
enrollment in the study.  
6. A patient who, in the opi[INVESTIGATOR_434059], is ineligible to 
participate in the study in consideration of patient’s safety.  
 
Investigational Product :  
JR-171 
 
Overall Design :  
This is a phase I/ II, open-label, multicenter (six sites in total are planned), multinational (Japan, 
Brazil and the US) study for the treatment of MPS I.  
 
Disclosure Statement:  
This is an open-label, first- in-human study of JR-171 designed to evaluate the safety, PKs and 
explore the efficacy.  
 
Dosing and Administration :  
Part 1  
Subjects aged 18  years or older shall receive an initial administration of JR-171 as an 
intravenous infusion at a dose of 0.1  mg per kg of body weight. The dose level shall be then 
increased to 1.0  mg/kg for the second administration, to 2.0  mg/kg for the third administration, 
and to 4.0  mg/kg at the fourth administration. When the principal investigator [INVESTIGATOR_434060]-[ADDRESS_550119] is discontinued from the study during the dose-escalation 
phase (until the safety evaluation of the fourth administration), the next third subject will stay 
in the hospi[INVESTIGATOR_434061] [ADDRESS_550120] aged 2-5  years (0-5 years in Japan and 
Brazil) shall each receive an initial dose of JR-171 as an intravenous infusion at a dose of 
1.0 mg per kg of body weight. The dose level shall be then increased to 2.0  mg/kg for the 
second administration, and to 4.0  mg/kg for the third administration. From the fourth to twelfth 
administrations, JR-171 shall be administered at 4.0  mg/kg. If the first subject aged 6-[ADDRESS_550121] aged 2-5  years (0-5 years in Japan and Brazil) is discontinued from the 
study during the dose-escalation phase (until the safety evaluation of the third administration) , 
the next subject for the same age group shall receive JR-171 in a dose-escalation manner as 
described above (the schedule of assessments will also be the same as those for the first 
subject in each age group).  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 10 / [ADDRESS_550122] aged 2-5  years (0-5 years in Japan and Brazil) can receive the initial 
administration at least [ADDRESS_550123] in each age 
group.  
Subjects other than the above of aged 2  years or older (any age in Japan and Brazil) shall be 
randomly assigned to either one of 2  groups in a 1:[ADDRESS_550124] body weight 
value collected at a scheduled visit.  
 
Concomitant Therapi[INVESTIGATOR_014]/Medications:  
Concomitant therapi[INVESTIGATOR_014]/medications can be used during this clinical study when required. 
Transfusions or maintenance transfusions for purpose of establishment an intravenous line, 
diluents for injections, bases for in-hospi[INVESTIGATOR_434062], disinfectants and drugs used in 
preparative treatments e.g., anesthetic (other than drugs with anticipated effects) are not 
considered as concomitant therapi[INVESTIGATOR_014]/medications. 
 
Prohibited Therapi[INVESTIGATOR_014]/Medications:  
Investigational products other than JR-[ADDRESS_550125]  
 
Number of Subjects 
Part 1 : 4 subjects  
Part 2 : Approximately 15 subjects in total.  
 
Duration of Study:  
 
Study start  
(e
nrollment start)  Enrollment end  Study end  Completion of 
da
ta analyses  
September [ADDRESS_550126] 2022 January 2023  
 
Pa
rt 1: 5-8 weeks (including 1-4  weeks as a screening period)  
Part 2 : 13-16 weeks (including 1-4  weeks as a screening period)  
 
Independent Data Safety Monitoring Committee (IDSMC) : Yes 
1.[ADDRESS_550127]- in-human study of JR-171, the JR-171-101 study will proceed in stages 
while confirming that safety is ensured. For the detailed procedures to confirm safety, refer to 
Section  6.6.1 . 
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 11 / 68 
 Part Number of subjects  Dose  
Part 1  4 subjects  Initial administration  : 0.1 mg/kg single dose  
Second administration  : 1.0 mg/kg single dose  
Third administration  : 2.0 mg/kg single dose  
Fourth administration  : 4.0 mg/kg single dose  
Part 2a), b) At least 2 subjectsc) Initial administration  : 1.0 mg/kg single dose  
Second administration  : 2.0 mg/kg single dose  
Third administration : 4.0 mg/kg single dose  
After third administration : 4.0 mg/kg/week , 9 times 
Twelve administrations in total 
2.0 mg/kg/week group: 
A
t least 6 subjects  
 
4.0 mg/kg/week group: 
At least 6 subjects  2.0 mg/kg/week, 12 times  
4
.0 mg/kg/week, 12 times  
a) Part 2 is started only after the safety is confirmed in Part 1 by [CONTACT_434117] . Su bjects participating in 
Part 1 are excluded from Part 2.  
b) Approximately [ADDRESS_550128] s will be enrolled in total.  
c) Starting dose of 1  mg/kg in the first subject aged 6-[ADDRESS_550129] aged 2-5 years (0-
5 years in Japan and Brazil).  
 
Subjects who complete Part 2 of the JR-171- 101 study will be eligible to participate in the 
extension study (protocol number: JR-171-102 study) and to continue receiving JR-171.  
 
Dosing Schema:  
 

JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 12 / 68 
 1.3 Schedule of Activities  
Part 1  
Observation/test timing  Pre-screening  Screening test  Registration  Baseline  Week 1  Week 2  Week 3  Week 4  Week 5  Discontinuation  
Visit window  - 28 days before Day  1 
(Da
y -28) to Day -[ADDRESS_550130] baseline characteristicsa)  X         
Assessment based on 
in
clusion/exclusion criteria    X        
Pregnancy testing (female subjects of 
ch
ildbearing potential only)   X         
Vital signsb)  Xc)  Xd) Xe) Xe) Xe) Xe) Xc), f) Xc) 
Laboratory testsf)  X  X  X X X X X 
Antibodiesf)    Xg)  Xh)   Xg) Xg) 
Plasma drug concentrationi)     X X X X   
Drug concentration in CSF     Xf)    Xj)  Xk) 
HS and DS concentrations in CSF     Xf)    Xj)  Xk) 
CSF opening pressure     Xf)    Xj)  Xk) 
Urinary HS and DS concentrations 
(in
cluding measurement of creatinine for 
concentration adjustment)f)    X  X X X X X 
Serum HS and DS concentrationsf)    X  X X X X X 
Liver and spleen volumesf)    X     X X 
Cardiac functionf)    X     X X 
Other clinical findings related to 
ne
urocognitive and behavioral changes            
12-lead electrocardiogramf)  X       X X 
Cross-reactive immunologic materiall)           
AEs           
Concomitant therapi[INVESTIGATOR_014]/medications      X X X X X X 
a) Neurocognitive testing and adaptive behavior assessment will be performed before the first infusion 
o
f JR- 171.  
b) Vital signs: pulse rate, body temperature, blood pressure, respi[INVESTIGATOR_697], percutaneous oxygen 
saturation and body weight. During the infusion of JR-171, it is necessary to monitor other than body 
weight (see Section 6.1 and 8.2.3 ). 
c) Ex
cluding body weight  
d) Only body weight is measured.  
e) Perform before and after administration of JR-171 except for body weight. Body weight will be 
measured at either measuring point.  f) Perform before administration of JR-171 (or before laronidase at Week 5, for subjects who will receive 
laronidase after completing the JR- 171-101 study)  
g) Anti-IDUA and anti- JR-171 antibodies  
h) Anti-JR-171 antibodies  
i) Blood specimens should be collected by [CONTACT_211906] “PK sampling schedule (plasma drug 
concentration) ”.  
j) Performed within 5 hours after the end of administration of JR- 171 
k) Performed if deemed feasible by [CONTACT_458] [INVESTIGATOR_249585]  
l) Samples will be collected once in Part 1 and obtained before JR-171 administration during the visit.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 13 / 68 
 Part 2  
Observation/test timing  Pre-screening  Screening test  Registration  Baseline  Week 1  Week 2  Week 3  Week 4  
Visit window  - Day -28 to Day -7  - Day -2 to Day 1  Day 1  Day 8 to 
Da
y 11a) Day 15 to 
Da
y 18a) Day 22 ±3 
Day 8 ±3b) Day 15 ±3b) 
JR-[ADDRESS_550131] baseline characteristicsc)  X       
Assessment based on 
in
clusion/exclusion criteria    X      
Allocation for treatment group    X      
Pregnancy testing (female subjects of 
ch
ildbearing potential only)   X       
Vital signsd)  Xe)  Xf) Xg) Xg) Xg) Xg) 
Laboratory testsh)  X  X  X  X 
Antibodiesh)    Xi)  Xj)  Xj) 
Plasma drug concentration b), k)     X   X 
Drug concentration in CSF     Xh)     
HS and DS concentrations in CSF     Xh)     
CSF opening pressure     Xh)     
Urinary HS and DS concentrations 
(in
cluding measurement of creatinine for 
concentration adjustment)h)    X  X  X 
Serum HS and DS concentrationsh)    X  X  X 
Liver and spleen volumesh)    X     
Cardiac functionh)    X     
6-minute walk testm)    Xh)     
Other clinical findings related to 
ne
urocognitive and behavioral changes          
12-lead electrocardiogramh)  X       
BVMT-R and HVLT-Rm)  Xp)       
T.O.V.A. m)  Xp)       
PedsQL-FIMn)  Xp)       
Cross-reactive immunologic materialo)         
AEs         
Concomitant therapi[INVESTIGATOR_014]/medications      X X X X 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 14 / 68 
 Part 2 cont.  
Observation/test timing  Week 5  Week 6  Week 7  Week 8  Week 9  Week 10  Week 11  Week 12  Week 13  Discontinu
ati
on 
Visit window  Day 29 ±3 Day 36 ±3 Day 43 ±3 Day 50±3 Day 57 ±3 Day 64 ±3 Day 71 ±3 Day 78 ±3 Day 85 ±3 Within 28 
da
ys from 
discontinu
ation  
JR-171 administration  X X X X X X X X   
Vital signsd) Xg) Xg) Xg) Xg) Xg) Xg) Xg) Xg) Xe), h) Xe) 
Laboratory testsh)  X  X  X  X X X 
Antibodiesh)    Xj)     Xi) Xi) 
Plasma drug concentrationb), k)        X   
Drug concentration in CSF         Xl)  Xm) 
HS and DS concentrations in CSF         Xl)  Xm) 
CSF opening pressure         Xl)  Xm) 
Urinary HS and DS concentrations 
(in
cluding measurement of creatinine 
for concentration adjustment)h)  X  X  X  X X X 
Serum HS and DS concentrationsh)  X  X  X  X X X 
Liver and spleen volumesh)         X X 
Cardiac functionh)         X X 
6-minute walk testm)         X X 
Other clinical findings related to 
ne
urocognitive and behavioral 
changes            
12-lead electrocardiogramh)         X X 
BVMT-R and HVLT-Rm)         Xq)  
T.O.V.A.m)         Xq)  
PedsQL-FIMn)         Xq)  
Cross-reactive immunologic materialo)           
AEs           
Concomitant therapi[INVESTIGATOR_014]/medications  X X X X X X X X X X 
a) The first subject aged 6- [ADDRESS_550132] aged 2-5  years (0-5 years in Japan and 
Brazil)  
b) Excluding the first subject aged 6- [ADDRESS_550133] aged 2-5  years (0-5 years in 
Japan and Brazil)  
c) Neurocognitive testing and adaptive behavior assessment will be performed before the first 
infusion of JR-171.  
d) Vital signs: pulse rate, body temperature, blood pressure , respi[INVESTIGATOR_697], percutaneous 
oxygen saturation and body weight. During the infusion of JR-171, it is necessary to monitor 
other than body weight (see Section 6.1 and 8.2.3 ). 
e) Ex
cluding body weight  
f) Only body weight is measured.  
g) Perform before and after administration of JR-171 except for body weight. Body weight will be 
measured at either measuring point.  h) Perform before administration of JR-171 (or before laronidase at Week  13, for subjects who 
will receive laronidase after completing the JR-171-101 study)  
i) Anti-IDUA and anti- JR-171 antibodies  
j) Anti-JR-171 antibodies  
k) Blood specimens should be collected by [CONTACT_211906] “PK sampling schedule (plasma drug 
concentration) ”. 
l) Performed within 5  hours after the end of administration of JR-171  
m) Performed if deemed feasible by [CONTACT_458] [INVESTIGATOR_249585]  
n) Only for subjects accompanied by [CONTACT_434118], caregiver or equivalent thereof.  
o) Samples will be collected once in Part 2 and obtained before JR-171 administration during the 
visit. 
p) Should be performed before the first infusion of JR-171.  
q) Visit window: ±10 days
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101  12 November 2021  
 15 / 68 
 PK sampling schedule (plasma drug concentration)  
Test timing  Part 1: Week 1, Week 2, Week 3 and Week 4  
Pa
rt 2: Week 1, Week 4 and Week 12 
Elapsed time  Before administration  1 hour after the start of 
a
dministration  At the end of 
ad
ministration  3 hours after the end 
o
f administration  6 hours after the end 
o
f administration  21 hours after the end 
o
f administration  
Time window (min)  -60 to 0  ±15 +10 ±15 ±15 ±60 
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 16 / 68 
 2. Introduction  
2.1 Study Rationale1) 
MP
S I is an autosomal recessive disorder caused by a deficiency of IDUA, a lysosomal enzyme 
involved in the breakdown of GAGs, which results in systemic accumulation of GAGs, 
particularly DS and HS. The accumulation of GAGs causes various symptoms, including 
deafness, otitis media, bone or joint deformity, joint contracture, obstructive respi[INVESTIGATOR_44447], 
apnea syndrome, cardiac valvulopathy, and CNS symptoms. MPS I is classified into three 
forms based on age of onset, clinical manifestation, severity, and degree of disease 
progression: Hurler syndrome, which is the most severe form, and Hurler-Scheie syndrome 
and Scheie syndrome, which are milder than Hurler syndrome. The most severe form, Hurler 
syndrome, clinically manifests in early childhood and progresses rapi[INVESTIGATOR_375]. It has been reported 
that approximately 75% of naïve patients with Hurler syndrome die before [ADDRESS_550134] CNS symptoms, whereas Scheie syndrome 
involves no CNS symptoms. Hurler-Scheie syndrome is of intermediate severity and involves 
only mild CNS symptoms or none at all.  
MPS I is a very rare disease, with an estimated prevalence of 0.11-3.62  per 100000  live births. 
In particular, the prevalence in Japan, the US, and Brazil is estimated to be 0.23, 0.34, and 
0.24 per 100000  live births, respectively.2) A study of 987 patients with MPS I registered in the 
Gl
obal MPS I Registry reported that Hurler syndrome, Hurler-Scheie syndrome, and Scheie 
syndrome accounted for 60.9%, 23.0%, and 12.9% of patients, respectively (unknown in 3.2% 
cases).3) 
MP
S I is usually treated with HSCT or ERT. HSCT is a treatment option for the severe form 
involving CNS symptoms. After HSCT, uptake of the enzyme secreted from the transplanted 
cells by [CONTACT_102]’s cells results in a reduction in accumulated GAGs and improvement of 
clinical symptoms ( e.g., hepatosplenomegaly, joint contracture, respi[INVESTIGATOR_1856]), and 
these effects are permanently maintained after successful engraftment. It has been reported 
that early HSCT preserves intellectual development. The management and treatment 
guidelines for MPS I recommend to select the therapy based on the risk/benefit ratio for HSCT 
versus ERT individually for each patient with MPS I.4) HSCT is recommended for patients 
<[ADDRESS_550135] for 
Hurler syndrome diagnosed before 2.5  years of age.5) However, HSCT may cause fatal 
com
plications such as graft-versus-host disease and infection. In [ADDRESS_550136]-transplant 5-year survival rate was 
reportedly 74%.6) Due to the aforementioned risks and the necessity of human leukocyte 
antigen-compatible donors, HSCT is not indicated for every patient.  
On the other hand, ERT is exogenous enzyme supplementation using cellular uptake of the 
enzyme via the cation-independent mannose-6-phosphate receptor (M6PR). Laronidase 
(laronidase solution for intravenous infusion; brand name: [CONTACT_434138]), the first enzyme 
preparation approved in the US and the Europe an Union (EU) in 2003, is indicated for patients 
with Hurler and Hurler-Scheie forms of MPS I and for patients with the Scheie form who have 
moderate to severe symptoms. Based on clinical study results and post-marketing experience 
over more than 10  years, laronidase is known to improve cardiopulmonary function, ability to 
walk, hepatosplenic volume, cardiac function, joint function, visual acuity, quality of life, etc. 
However, laronidase, which does not penetrate the blood-brain barrier, is not effective for CNS 
symptoms.7) 
 
In
 conclusion, early HSCT is effective for CNS symptoms of MPS I, but there are risks and an 
upper age limit for treatment. ERT is shown to be effective for systemic symptoms, but not for 
CNS  symptoms. Therefore, it is desirable to establish a safe and effective treatment for MPS  I 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 17 / 68 
 that also address es the CNS symptoms.  
2.2 Background  
JR-171 is a fusion protein genetically modified to penetrate the blood-brain barrier and consists 
of IDUA and the Fab fragment of a humanized antibody that specifically recognizes human 
transferrin receptor 1 (hTfR).  
JR-171, which binds to hTfR and M6PR, may be transported to the cerebral parenchyma via 
hTfR on the cerebrovascular endothelium and to peripheral organ cells via M6PR and hTfR. 
In a repeated dose study where human transferrin receptor 1 knock-in/α-L-iduronidase knock-
out mice (hTfR KI/Idua KO mice), an animal model of MPS I, received JR-[ADDRESS_550137] 
a clinical study of JR-171, which is an innovative treatment for MPS I of high clinical 
significance, the sponsor is planning a phase I/II study in patients with MPS I.  
2.3 Benefit/Risk Assessment  
2.3.1 Known Potential Risks  
As JR-171 contains anti-hTfR antibody, the ordinary iron transport system (binding of 
transferrin to the transferrin receptor) might be inhibited, which may lead to the development 
of adverse drug reactions (anemia, etc.). JR-171 is also considered to cross the blood-brain 
barrier, and adverse drug reactions (vomiting, headache, etc.) may therefore occur. 
Furthermore, the enzyme portion of JR-[ADDRESS_550138] been conducted to date. 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 20 / 68 
 4. Study Design  
4.1 Overall Design  
A Phase I/II, open-label, multicenter (six sites in total are planned), multinational (Japan, Brazil 
and the US), designed to evaluate the safety, PKs and explore the efficacy for the treatment 
of MPS I. 
 
The JR-171-[ADDRESS_550139] is discontinued from the 
study during the dose-escalation phase (until the safety evaluation of the fourth administration), 
the next third subject will stay in the hospi[INVESTIGATOR_434061] [ADDRESS_550140] aged 2-5 years (0-5 years in 
Japan and Brazil) shall each receive an initial dose of JR-171 as an intravenous infusion at a 
dose of 1.0 mg per kg of body weight. The dose level shall be then increased to 2.0 mg/kg for 
the second administration, and to 4.0 mg/kg for the third administration. From the fourth to 
twelfth administrations, JR-171 shall be administered at 4.0 mg/kg. If the first subject aged 6-
[ADDRESS_550141] aged 2-5 years (0-5 years in Japan and Brazil) is discontinued from 
the study during the dose-escalation phase (until the safety evaluation of the third 
administration), the next subject for the same age group shall receive JR-171 in a dose-
escalation manner as described above (the schedule of assessments will also be the same as 
those for the first subject in each age group). 
The first subject aged 2-5  years (0-5 years in Japan and Brazil) can receive the initial 
administration at least [ADDRESS_550142] in each age 
group.  
Subjects other than above of 2 years or older (any age in Japan and Brazil) shall be randomly 
assigned to one of either 2 groups in a 1:1 ratio and receive 2.0 or 4.0 mg/kg of JR-171. 
Since this is a first- in-human study of JR-171, the JR-171-101 study will proceed in stages 
while confirming that safety is ensured. For the detailed procedures to confirm safety, refer to 
Section 6.6.1 . 
Su
bjects who complete Part 2 of the JR-171-101 study will be able to participate in the 
extension study (protocol number: JR-171-102 study) and continue receiving JR-171. 
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 21 / 68 
 Part Number of subjects  Dose  
Part 1  4 subjects  Initial administration  : 0.1 mg/kg single dose  
Second administration  : 1.0 mg/kg single dose  
Third administration  : 2.0 mg/kg single dose  
Fourth administration  : 4.0 mg/kg single dose  
Part 2a), b) At least 2 s ubjectsc) Initial administration  : 1.0 mg/kg single dose  
Second administration  : 2.0 mg/kg single dose  
Third administration : 4.0 mg/kg single dose  
After third administration : 4.0 mg/kg/week, 9 times 
Twelve administrations in total  
2.0 mg/kg/week group: 
A
t least 6 subjects  
 
4.0 mg/kg/week group: 
At least 6 subjects  2.0 mg/kg/week, 12 times  
4
.0 mg/kg/week, 12 times  
a) Part 2 is started only after the safety is confirmed in Part 1 by [CONTACT_434117] . Su bjects participating in 
Part 1 are excluded from Part 2.  
b) Approximately [ADDRESS_550143] s will be enrolled in total.  
c) Starting dose of 1  mg/kg in the first subject aged 6-[ADDRESS_550144] aged 2-5 years (0-
5 years in Japan and Brazil).  
 
 
4.2 Scientific Rationale for Study Design  
JR-171 is expected to provide clinical benefit to MPS I patients especially those who show 
CNS manifestations. Since many patients with MPS I are receiving ERT8) or/and have received 
an
 HSCT,5) and it is very difficult to enroll naïve patients, the JR -171-[ADDRESS_550145] ’s body within 1  week because its mean t 1/2 ranges from 1.5 to 3.6 hours. Moreover, 

JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 22 / 68 
 given that there is no evidence of accumulation of laronidase,7) no extended washout period 
pr
ior to switching from laronidase is included to evaluate the safety and exploratory efficacy of 
JR-171. Since interruption of ERT for MPS I over a certain period of time may result in 
irreversible progression of the disease, no placebo control group is included from an ethical 
perspective. The JR-171-[ADDRESS_550146]- in-human study of JR-171, in Part 1, four MPS I patients aged 18 years or 
older will receive 4 times JR-171 administration in a weekly dose-escalation manner. When it 
is concluded that there are no safety issues in Part 1 and JR-171 can be shown to potentially 
penetrate the blood-brain barrier in humans, treatment in Part 2 will be started in approximately 
15 subjects with MPS I. 
Since no accumulation of HS and DS is observed in non-MPS patients,9), 10) and there are risks 
th
at the administration of protein drug to healthy volunteers, in terms of neutralizing antibody 
production, this phase I/II study is conducted in subjects with MPS I to assess the relationship 
between PKs and pharmacodynamics. 
The nonclinical safety of JR-171 was demonstrated in a repeated intravenous dose toxicity 
study where male and female cynomolgus monkeys received JR-171 at a dos age of 40 mg/kg 
once a week for 4 weeks. Furthermore, a 13-week toxicity study will be completed before this 
phase I/II recruits subjects. Given a decrease in accumulated GAGs in the brain and other 
peripheral organs in a repeated intravenous dose study where hTfR KI/Idua KO mice received 
JR-[ADDRESS_550147]-level (NOAEL) of 40 mg/kg in a nonclinical toxicity study 
in male and female cynomolgus monkeys, dose equivalence in human is calculated to be 
approximately 1.0 mg/kg with safety margin of 10. In this first- in-human study of JR-171 one-
tenth of the aforementioned dose is selected as the initial dose level in Part 1 for safety 
considerations, and the dose level is increased each week. 
In a repeated dose study where hTfR KI/Idua KO mice received JR-171 once every week or 
once every 2 weeks for 12 weeks, the drug at dos ages of 2.0 and 4.0 mg/kg/every 2 weeks 
was shown to be as effective for systemic symptoms as laronidase at dos age of 
0.58 mg/kg/week. In addition, unlike laronidase, JR-171 also decreased HS and DS 
concentrations in the brain and CSF at all doses. However, slightly greater reductions in the 
HS and DS levels in some tissues were observed in treatment groups receiving every week 
regimen than the treatment groups receiving every 2 weeks dosing regimen. Furthermore, 
based on the results of nonclinical pharmacology, ADME, and toxicology studies, it is 
considered that there are no serious safety concerns in intravenous administration of JR-171 
to MPS I patients at the dose levels up to 4 .0 mg/kg, which is the planned maximum dose in 
Phase I/II study. 
Based on these findings, 2.0 and 4.0 mg/kg were selected as doses to be administered every 
week in Part [ADDRESS_550148] received 2.0 or 4.0 mg/kg for weekly administration. 
Considering the safety for subjects under [ADDRESS_550149] aged 2-5 years (0-5 years in Japan and Brazil) in Part 2 will each receive the 
administration of JR-171 by [CONTACT_2715]-escalation manner , and its initial dose of JR-171 shall start 
from 1.0 mg/kg. A previous report indicated that concentration of soluble transferrin receptor 
gradually decreases from the neonatal period to adolescence, and then reduces further to the 
adult level after which the concentration remains stable.11) However, no marked reduction of 
th
e soluble transferrin receptor was found in adults, indicating that effect of JR-[ADDRESS_550150] ’s age . Therefore , the initial dose of JR-171 shall start from 
1.0 mg/kg as part of dose-escalation, and 2 years (0 years in Japan and Brazil) or older 
patients, including naïve ones, can also be enrolled in consideration of ethical perspective 
because it is desirable to start treatment earlier in order to suppress progressive 
neurodegeneration. Second and subsequent subjects under 18 years in each age group will 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 23 / 68 
 receive 2.0 or 4.0 mg/kg for weekly administration, after the safety evaluation of the third 
administration of the first subject. 
4.[ADDRESS_550151] completed the study if he/she has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the Schedule of Activities, 
Section  1.3. 
 
The
 end of the study is defined that the point of when all subjects complete all procedures 
relating to the JR-171-[ADDRESS_550152] meet all of the 
inclusion criteria, and none of the exclusion criteria.  
5.1 Inclusion Criteria  
Patients are eligible to be included in the study only if all of the following criteria apply:  
 
1. A patient aged 18 years or older in Part 1, or 2  years or older (any age in Japan and Brazil) 
in Part  2, at the time of informed consent.  
2. A patient from whom written informed consent can be obtained. If the patient is aged under 
18 years (20  years in case of Japan) at the time of assent or willingness to participate in 
the study cannot be confirmed due to MPS I-related intellectual disability, informed 
permission from the patient’s legally acceptable representative ( e.g., his/her parents or 
guardians) needs to be obtained instead of his/her consent. Even in this case, written 
informed consent should be obtained from the patient, wherever possible.  
3. A patient diagnosed with MPS I based on any one of the following criteria:  
 Activity of the IDUA enzyme below 10% of the lower reference level in leucocytes or 
cultured skin fibroblasts, AND increased age-related urinary levels of GAGs (before 
ERT).  
 Activity of the IDUA enzyme below 10% of the lower reference level in leucocytes or 
cultured skin fibroblasts, AND presence of one pathogenic mutation in each of the 
alleles of the IDUA gene.  
 Increased age-related urinary levels of GAGs (before ERT), AND presence of one 
pathogenic mutation in each of the alleles of the IDUA gene.  
4. A patient diagnosed as having mild or no MPS I-related intellectual disability (able to report 
their own subjective symptoms) by [CONTACT_458] [INVESTIGATOR_249585] (Part  1 
only).  
5. A patient who has received laronidase continuously for at least 12  weeks and has received 
laronidase at a stable dosage for the 2  weeks immediately before the initial administration 
of JR-171 (except for a laronidase naïve patient or a patient who has previously been 
treated by [CONTACT_59513]).  
6. Female patient or male patient whose co-partner is of child-bearing potential agrees to 
use a medically accepted, highly effective method of contraception, such as spermatocidal 
gel plus condom, an intrauterine device or oral contraceptives until one month after the 
final administration.  
Rationale for the Inclusion Criteria:  
1. In this first in human study of JR-171, the minimum age of 18  years was defined in Part  1 
for safety considerations. In Part 2, pediatric patients will be also eligible to participate 
since treatment of MPS I often starts in childhood.  
2. Signed informed consent ( i.e., written consent) is necessary for the study registration.  
3. This criterion  was defined to enroll only patients with MPS I in the study.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 24 / [ADDRESS_550153] and 
evaluate safety information carefully.  
5. The result of the phase I/II study for laronidase showed that urinary GAG concentrations 
was 60  to 80% below the baseline after 8 to 12  weeks of intravenous administration of 
Aldurazyme.12) Based on these results, we set the duration of laronidase  administration 
before the initial administration of JR-[ADDRESS_550154] not been proven when JR-171 is administered to patients with MPS I.  
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in the 
JR-171-101 study:  
 
1. A patient who has received gene therapy treatment. 
2. A patient who, in the opi[INVESTIGATOR_434059], cannot 
undergo lumbar puncture, including those who have a difficulty in taking position for lumbar 
puncture due to joint contracture and those who are likely to develop dyspnea during 
lumbar puncture. 
3. A patient who is pregnant or lactating. 
4. A patient who has developed serious drug allergy or hypersensitivity to any drugs, in the 
opi[INVESTIGATOR_434059], is inappropriate for participation in 
the study. 
5. A patient who has received another investigational product within the 12 months prior to 
enrollment in the study. 
6. A patient who, in the opi[INVESTIGATOR_434059], is ineligible to 
participate in the study in consideration of patient ’s safety. 
Rationale for the Exclusion Criteria:  
1. CNS and systemic symptoms could have been alleviated in patients responsive to gene 
therapy treatment. This criteri on was defined to explore the efficacy of JR-[ADDRESS_550155] not been proven at the point that JR-171 is administered to 
patients with MPS I. 
4. This criterion  was defined in consideration of the patient’s  safety. 
5. This criterion  was defined in consideration of the patient’s  safety. 
6. This criterion  was defined in consideration of the patient’s  safety. 
5.3 Lifestyle Considerations  
It is not applicable for the JR-171-101 study.  
5.4 Screen Failures  
Screening failures are defined as subjects for whom consent to participate in the clinical study 
is given but who are not registered in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure subjects, to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure details 
and eligibility criteria. 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 25 / 68 
 5.5 Strategies for Recruitment and Retention  
 Target: Male or female MPS I patients  
 Target sample size:  
Part 1: 4 subjects ( 18 years or older) 
Part 2: Approximately 15 in total  
 Description of sites/facilities enrolling subjects: 6 sites (Japan, Brazil and the US) are 
planned.  
 
For compensation or any incentives that subjects may receive, please refer to the informed 
consent documents.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 26 / [ADDRESS_550156] according to the study protocol.  
6.1 Study Interventions Administered  
Intervention Name   Investigational product name (Code): JR- 171  
 Generic name:  
[CONTACT_434139] (INN) and application under 
preparation for Japanese Accepted Names for 
Pharmaceuticals (JAN)  
Dosing and  
ad
ministration  Part 1  
Su
bjects aged 18  years or older shall receive an initial 
administration of JR-171 as an intravenous infusion at a dose of 
0.1 mg per kg of body weight. The dose level shall be then 
increased to 1.0  mg/kg for the second administration, to 2.0  mg/kg 
for the third administration, and to 4.0  mg/kg at the fourth 
administration. When the principal investigator [INVESTIGATOR_434060]-[ADDRESS_550157] is discontinued from the 
study during the dose-escalation phase (until the safety evaluation 
of the fourth administration), the next third subject will stay in the 
hospi[INVESTIGATOR_434061] [ADDRESS_550158] aged 2-
5 years (0-5  years in Japan and Brazil) shall each receive an 
initial dose of JR-171 as an intravenous infusion at a dose of 
1.0 mg per kg of body weight. The dose level shall be then 
increased to 2.0  mg/kg for the second administration, and to 
4.0 mg/kg for the third administration. From the fourth to twelfth 
administrations, JR-171 shall be administered at 4.0  mg/kg. If the 
first subject aged 6-[ADDRESS_550159] aged 2-5  years (0-
5 years in Japan and Brazil) is discontinued from the study during 
the dose-escalation phase (until the safety evaluation of the third 
administration), the next subject for the same age group shall 
receive JR-171 in a dose-escalation manner as described above 
(the schedule of assessments will also be the same as those for 
the first subject in each age group).  
The first subject aged 2-5  years (0-5  years in Japan and Brazil) 
can receive the initial administration at least [ADDRESS_550160] in each age group is completed.  
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 30 / [ADDRESS_550161] when a principal 
investigator [INVESTIGATOR_434063].  
6.6 Dosing and Administration  
6.6.1 Confirmation of Safety  
Part 1 : Doses in Part 1 are 0.1, 1.0, 2.0, 4.0  mg/kg and will be administered to a subject at 
intervals of [ADDRESS_550162], JR-171 will be increased to the next dose upon approval of 
the sponsor.  
The sponsor will establish an IDSMC. If any IARs with Common Terminology Criteria 
for Adverse Events (CTCAE) grade ≥ III occur up to [ADDRESS_550163] is discontinued from the study during the dose-
escalation phase (until the safety evaluation of the fourth administration), the next third 
subject will stay in the hospi[INVESTIGATOR_434061] 21  hours after the end of 
each administration to assess safety.  
After completing the clinical study for all subjects who participated in Part 1, the 
sponsor will convene the IDSMC and ask their opi[INVESTIGATOR_434064] 2 based on all safety data collected from the start of administration 
to Week  5. After taking into consideration the opi[INVESTIGATOR_434065], when the sponsor 
concludes, that initiation of Part  2 will pose no problem, from ethical, scientific, and 
medical perspective, then Part 2 may be initiated.  
 
Part 2 : The first subject aged 6- [ADDRESS_550164] aged 2-5  years (0-5 years in 
Japan and Brazil) shall each receive an initial dose of JR-171 as an intravenous 
infusion at a dose of 1.0  mg per kg of body weight. The dose level shall be then 
increased to 2.0  mg/kg for the second administration, and to 4.0  mg/kg for the third 
administration. From the fourth to twelfth administrations, JR-171 shall be 
administered at 4.0  mg/kg. If the first subject aged 6- [ADDRESS_550165] aged 
2-5 years (0-5 years in Japan and Brazil) is discontinued from the study during the 
dose-escalation phase (until the safety evaluation of the third administration), the next 
subject for the same age group shall receive JR-171 in a dose-escalation manner as 
described above (the schedule of assessments will also be the same as those for the 
first subject in each age group).  
The first subject aged 2-5  years (0-5 years in Japan and Brazil) can receive the initial 
administration at least [ADDRESS_550166] aged 6- 17 years receives the initial 
administration.  
Subjects other than the above of aged 2  years or older (any age in Japan and Brazil) 
shall be allocated to receive either 2.0 or 4.0  mg/kg/week JR-171 group . The safety 
evaluation in Part  2 will be conducted in subjects aged 2- 17 years (0-17 years in Japan 
and Brazil). The first subject aged 6-17 years will stay in the hospi[INVESTIGATOR_434066] 21  hours after the end of each administration at Week  1, Week  2 and 
Week  3 to assess safety. When the principal investigator [INVESTIGATOR_249585], and the 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 31 / [ADDRESS_550167] 
administration , the second and subsequent subjects aged 6- 17 years can be assigned 
to either 2.0 or 4.0  mg/kg/week JR-171 group. If any IARs with CTCAE grade ≥ III 
occur up to [ADDRESS_550168] aged 2-5  years (0-5 years in Japan and Brazil) can receive the initial 
administration at least [ADDRESS_550169] aged 2-5  years (0-5 years in Japan and Brazil) will 
stay in the hospi[INVESTIGATOR_434061] [ADDRESS_550170] aged 2-5  years 
(0-5 years in Japan and Brazil) after the end of third administration, the second and 
subsequent subjects aged 2-5  years (0-5 years in Japan and Brazil) can be assigned 
to either of 2.0 or 4.0  mg/kg/week JR-171 group. If any IARs with CTCAE grade ≥ III 
occur up to [ADDRESS_550171] aged 2-5  years (0-5 years in Japan and Brazil), the 
sponsor should convene the IDSMC and ask their opi[INVESTIGATOR_434067]-171 dose increase.  
 
The sponsor’s Safety Evaluation Manual in a separate document will be followed for the 
confirmation of safety procedure.  
6.[ADDRESS_550172] whose co-partner is of childbearing potential is required 
to refrain from conception during the study period and/or to use an adequate method of 
contraception. The subject or co-partner should contact [CONTACT_458] [INVESTIGATOR_434068].  
2. The subject and co-partner must be willing to use a medically accepted, highly effective 
method of contraception, such as spermatocidal gel plus condom, an intrauterine device 
or oral contraceptives.  
3. The subject or co-partner must use an adequate method of contraception until one month 
after the final administration.  
6.8 Intervention after the End of the Study  
The sponsor is planning an extension study of the Study JR-171-101 of over 5  years ’ duration 
to confirm the long-term safety and efficacy of JR-171.  
7. Discontinuation of Study Intervention and Subject Discontinuation  
/Withdrawal  
7.1 Discontinuation of Study Intervention  
7.1.1 Criteria for Termination or Suspension  
The sponsor will consider the discontinuation/cessation of the whole or part of the clinical study 
in any situation described in the information below. In this case, all principal investigators will 
be immediately informed by [CONTACT_456].  
1. Occurrence of a serious adverse event (SAE) with CTCAE grade ≥ IV 
2. Occurrence of serious adverse drug reactions coded to same prefer red term (PT) in 2 or 
more subjects  
3. A research report that suggests the tendency of occurrence of adverse drug reactions, 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 32 / [ADDRESS_550173], leading to a situation where the 
proper continuation of the clinical study is considered problematic  
8. When the continuation of the clinical study is considered difficult due to changes of the 
structure or environment for conducting the clinical study ( e.g., a transfer of the principal 
investigator)  
9. Other cases in which the continuation of the clinical study is considered inappropriate due 
to new information or a change in the situation identified during the clinical study  
 
When the clinical study is discontinued the following examinations/observations described 
below are to be performed as much as possible, if the subject agrees, after final administration 
of the investigational product. The details should be recorded in the eCRF listed below except 
for items 3, 4, 5, [ADDRESS_550174] measurements in the eCRF. The  date of 
discontinuation and the reason for discontinuation will also be recorded in the eCRF.  
1. Vital signs (pulse rate, body temperature, blood pressure , respi[INVESTIGATOR_434069])  
2. Laboratory tests (hematologic test, blood biochemical test, determination of serum iron 
levels, and urinalysis)  
3. Antibody tests (anti-IDUA and anti-JR-171 antibodies)  
4. Drug concentration in CSF  
5. HS and DS concentrations in CSF 
6. CSF opening pressure 
7. Urinary HS and DS concentrations 
8. Urinary creatinine  
9. Serum HS and DS concentrations  
10. Liver and spleen volumes  
11. Cardiac function  
12. 6-minute walk test (Part 2 only)  
13. Other clinical findings related to neurocognitive and behavioral changes  
14. 12-lead electrocardiogram  
15. AEs 
16. Concomitant medications/therapi[INVESTIGATOR_434070] a subject and the frequency of lumbar puncture. For items [ADDRESS_550175] measurements in the eCRF. For the reporting of the results, data should 
be reported by [CONTACT_25699].  
1. Drug concentration in CSF  
2. HS and DS concentrations in CSF 
3. CSF opening pressure 
 
After completion of examinations/observations at discontinuation, the principal investigator [INVESTIGATOR_434071] (re)starting of laronidase in consideration of 
the subject’s status ( e.g., progression to underlying disease or a significant worsening of their 
clinical parameters including serum and urinary HS and DS concentrations ). 
7.[ADDRESS_550176] Discontinuation/Withdrawal from the Study  
Subjects are free to withdraw from participation in the study at any point of time upon request 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 33 / [ADDRESS_550177] from the study 
for the following reasons:  
1. When a subject or his/her legal representative wishes to discontinue the clinical study  
2. When the continuation of the study became impossible for reasons including a transfer to 
another hospi[INVESTIGATOR_307]/change of address during the clinical study  
3. When a subject was found to be ineligible after the start of the clinical study such that 
continued participation would compromise safety of the subject or integrity of the study  
4. When the continuation of the clinical study becomes impossible for reasons including the 
occurrence of an AE* 
5. When a subject experiences anaphylactic shock  
6. Other cases in which the principal investigator [INVESTIGATOR_434072]  
 
*When the occurrence of an SAE with CTCAE grade ≥ IV, the principal investigator [INVESTIGATOR_434073]/temporary cessation of the study. If the 
principal investigator [INVESTIGATOR_434074] a causal relationship with JR-[ADDRESS_550178] be discontinued.  
 
For examinations/observations at the time of the subject discontinuation from the study, see 
Section  7.1.[ADDRESS_550179] the information in the eCRF.  
 
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1 
(see Section  10.1.18 ). 
8. Stu
dy Assessments and Procedures  
 Study procedures and their timing are summarized in the Schedule of Activities . 
Protocol waivers are not allowed.  
 Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the subject should continue or discontinue 
study intervention.  
 Adherence to the study design requirements, including those specified in the 
Schedule of Activities, is essential and required for study conduct.  
 All screening evaluations must be completed and reviewed to confirm that potential 
subjects meet all eligibility criteria. The principal investigator [INVESTIGATOR_17459] a screening 
log to record details of all subjects screened and to confirm eligibility or record reasons 
for screening failure, as applicable.  
 Procedures conducted as part of the subject’s routine clinical management ( e.g., 
blood count) and obtained before signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol-specified criteria and 
were performed within the time frame defined in the Schedule of Activities.  
8.1 Demographic and Other Baseline Characteristics  
The following will be investigated and recorded in the eCRF:  
 Date of written consent obtained from the subject and, if applicable, written permission 
from his/her legally acceptable representative  
 Age at the time of informed consent  
 Date of diagnosis of MPS I  
 Presence or absence of use of laronidase, and start date (if applicable)  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 35 / 68 
 menopausal for more than 1 year prior to the time of informed consent or surgically sterile). In 
the eCRF, whether or not a measurement has been performed as well as the sample collection 
date and results of measurement, if performed, should be record ed. 
8.2.2 Administration Information  
For each dose of JR-171, the status of administration should be recorded in the eCRF: whether 
or not JR-171 has been administered, date of administration, start time of administration, 
ending time of administration, start time of interruption if applicable, time of administration 
resumed if applicable, applied dose, whether or not administration has been 
discontinued/interrupted, whether or not the infusion rate has been reduced.  
8.2.3 Vital Signs  
Pulse rate, body temperature, blood pressure (systolic and diastolic blood pressure) 
respi[INVESTIGATOR_697], and percutaneous oxygen saturation will be measured before and after 
administration of JR-[ADDRESS_550180] to be recorded in the eCRF, 
but if AEs occur, the detail of the AEs should be recorded in the eCRF.  
8.2.4 Laboratory Tests  
Blood and urine will be collected before administration of JR-171 or laronidase to measure the 
parameters listed below. In the eCRF, whether or not a measurement has been performed as 
well as the sample collection date and results of measurement, if performed, should be 
recorded.  
[IP_ADDRESS] Hematology  
White blood cell count, differential leukocyte count, red blood cell count, hemoglobin, 
hematocrit, platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration (MCHC), reticulocyte ratio, prothrombin 
time, and activated partial thromboplastin time (APTT).  
[IP_ADDRESS] Biochemistry  
Total protein, albumin, albumin/globulin ratio, haptoglobin, CK, total bilirubin, aspartate 
aminotransferase (AST [GOT]), alanine transaminase (ALT [GPT]), γ-GT (γ-GTP), alkaline 
phosphatase (ALP), total cholesterol, triglycerides, creatinine (enzymatic method), Na, K, Cl, 
Ca, and P.  
[IP_ADDRESS] Serum Iron Tests  
Serum iron, unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC), ferritin, 
and transferrin saturation (TSAT).  
[IP_ADDRESS] Urinalysis  
Determination of glucose, protein, and occult blood.  
8.2.[ADDRESS_550181] M6PR 
binding and hTfR binding of JR-171 will be measured.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 36 / [ADDRESS_550182] before administration of JR-171 or laronidase 
to measure anti-IDUA and anti-JR-171 antibodies. In the eCRF, whether or not a measurement 
has been performed and, if applicable, the sample collection date should be recorded. Data 
should be reported by [CONTACT_25699].  
8.2.6 12-lead Electrocardiogram  
Electrocardiography will be performed before administration of JR-171 or laronidase. In the 
eCRF, whether or not a measurement has been performed as well as the date of measurement 
and the presence or absence of abnormal finding, including its details and whether or not it will 
be considered an AE, should be recorded.  
8.2.7 Concomitant Medication/Therapy  
All concomitant medications/therapi[INVESTIGATOR_434075]  [ADDRESS_550183] visit (Week  5 in Part  1/Week  13 in Part  2, or discontinuation). In the eCRF, 
presence or absence of usage of concomitant medication/therapy, and if applicable, its details 
(see Section  6.5) should be recorded.  
Rat
ionale for the Safety Assessments  
For the safety evaluation, systemic endpoints, that is, AEs (see Section  8.3), laboratory tests, 
vit
al signs, and 12-lead electrocardiogram were selected. Serum iron tests were included 
based on the involvement of TfR, which is responsible for iron transport, in the mechanism of 
cellular uptake of JR-171.  
8.[ADDRESS_550184] (or, when appropriate, by a caregiver, surrogate, or the 
subject’s legally authorized representative).  
The principal investigator [INVESTIGATOR_434076], 
documenting, and recording events that meet the definition of an AE or SAE (Appendix 2 (see 
Section  10.2.1  and 10.2.3 )) and remain responsible for following up on A Es that are serious, 
considered related to the study intervention or study procedures, or that caused the subject to 
discontinue the study (see Section  7). 
If
 an AE occurs, the name, severity, seriousness, day of onset, presence or absence of 
treatment for study treatment, outcome of the AE (including date of assessment), relationship 
between the AE and investigational product, comments as appropriate , and whether or not 
with IAR should be recorded in the eCRF.  
8.3.[ADDRESS_550185] visit (Week  5 
in Part  1/Week  13 in Part  2, or discontinuation) at the time points specified in the Schedule of 
Activities (see Section  1.3). Events occurring within 28 days after the time of observation at 
W
eek 5 in Part 1/Week [ADDRESS_550186] will be collected as adverse drug reactions in the JR-171-101 study, 
except for events that are occurred during the extension study of the JR-171-101 study (JR-
171-102). In the eCRF, presence or absence of AEs and, if applicable, its details (Appendix 2 
(see Section  10.2.4 )) should be recorded.  
D
ata of MPS I-related medical occurrences that begin before obtaining informed consent will 
be recorded in the Medical History/Current Medical Conditions section of the case report form 
not in the AE section.  
All SAEs will be recorded and reported to the sponsor immediately and under no circumstance 
should exceed 24  hours, as indicated in Appendix 2 (see Secti on 10.2). The principal 
in
vestigator will submit any updated SAE data to the sponsor within 24  hours of it being 
available.  
Principal investigators are not obligated to actively seek AEs or SAEs after conclusion of the 
study participation. However, if the principal investigator [INVESTIGATOR_434077], including a death, 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 37 / [ADDRESS_550187] has been discharged from the study, and he/she considers the event 
to be reasonably related to the study intervention or study participation, the principal 
investigator [INVESTIGATOR_434078].  
8.3.2 Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2 (see 
Section  10.2.4 ). 
Ca
re will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about AE 
occurrences.  
8.3.3 Follow-up of AEs and SAEs  
After the initial AE/SAE report, the principal investigator [INVESTIGATOR_434079]/contacts. All AEs, and AEs of special interest (see Section  8.3.6 ), 
wi
ll be followed until resolution, stabilization, or the event is otherwise explained. Further 
information on follow-up procedures is provided in Appendix 2 (see Section  10.2.4 ). 
8.3
.4 Regulatory Reporting Requirements for SAEs  
 Prompt notification by [CONTACT_458] [INVESTIGATOR_434080] a study intervention under clinical investigation are met.  
 The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB/Independent Ethics 
Committees (IEC), and principal investigators.  
 For all studies except those utilizing medical devices principal investigator [INVESTIGATOR_434081] 
(S[LOCATION_003]R) according to local regulatory requirements and sponsor policy and 
forwarded to principal investigators as necessary.  
 A principal investigator [INVESTIGATOR_434082] a principal investigator [INVESTIGATOR_434083] ( e.g., summary or listing of SAEs) from 
the sponsor will review and then file it along with the Investigator’s Brochure and will 
notify the IRB/IEC, if appropriate according to local requirements.  
8.3.5 Pregnancy (Female Subjects and Subject’s Female Co-partners of 
Childbearing Potential Only)  
 For female subjects, details of all pregnancies in childbearing potential (female 
subjects of non-childbearing potential are confirmed by [CONTACT_434119]-menopausal 
for more than 1 year prior to the time of informed consent or surgically sterile) will be 
collected after the start of study intervention and until a miscarriage , an abortion or 1 
month after the delivery. The follow-up for infants will be about one month after the 
birth.  
 If a pregnancy is confirmed in a female subject or subject’s female co-partner of 
childbearing potential, the principal investigator [INVESTIGATOR_434084] 
24 hours of learning of the pregnancy using the designated form.  
 Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
 For female subjects, whether or not a measurement of pregnancy testing has been 
performed as well as the sample collection date and results of measurement, if 
performed, should be recorded in the eCRF.  
8.3.[ADDRESS_550188], when the AEs 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 38 / 68 
 described below occur, they will be defined as significant AEs and evaluated.  
 
 Anaphylaxis, anaphylactic shock  
Cutaneous symptoms including urticaria, digestive symptoms including abdominal 
pain and vomiting, respi[INVESTIGATOR_434085] a feeling of dyspnea, and shock 
symptoms including sudden pallor and clouding of consciousness are called 
anaphylaxis. When the principal investigator [INVESTIGATOR_434086], refer to criteria described below.16) A condition in which a sharp drop in 
bl
ood pressure occurs and symptoms like disturbance of consciousness are seen is 
specifically called anaphylactic shock.  
 
When any [ADDRESS_550189] the event as an anaphylaxis.  
1. Acute onset of an illness (minutes to hours) with involvement of Skin/mucosal 
tissue ( e.g., hives, generalized itch/flush, swollen lips/tongue/uvula)  
AND  
Compromised airway ( e.g., dyspnea, wheeze/bronchospasm, stridor, reduced 
peak expi[INVESTIGATOR_10229])  
OR 
Reduced blood pressure or associated symptoms ( e.g., hypotonia, syncope)  
2. Two or more of the following after exposure to known allergen for that patient 
(minutes to hours)  
History of severe allergic reaction  
Skin/mucosal tissue symptoms ( e.g., hives, generalized itch/flush, swollen 
lips/tongue/uvula)  
Compromise airways ( e.g., dyspnea, wheeze/bronchospasm, stridor, reduced 
peak expi[INVESTIGATOR_10229])  
Reduced blood pressure or associated symptoms ( e.g., hypotonia, syncope)  
In suspected food allergy: gastrointestinal symptoms ( e.g., crampy abdominal 
pain, vomiting)  
3. Hypotension after exposure to known allergen for that patient (minutes to hours)  
Infants and children: low systolic blood pressure (age-specific) or >30% drop in 
systolic blood pressure*  
Adults: systolic blood pressure , <100  mm Hg or >30% drop from the last 
measurement  
Caution: These criteria describe so-called classic cases of anaphylaxis. Other 
presentations may also indicate anaphylaxis ( e.g., early presentation, 
generalized flushing; isolated presentation, sudden hypotension only in a 
patient without evidence of allergen exposure; classic presentation but with 
a non-allergenic cause, such as exercise). Conversely, clinicians need to 
remember the potential for false-positive symptoms or signs ( e.g., difficulty 
breathing from panic, faintness from vasovagal epi[INVESTIGATOR_1865]).  
*Low systolic blood pressure for children is defined as < 70 mm Hg from 1 month to 
1 year; less than (70  mm Hg + (2 × age)) from 1 to 10  years; and < 90 mm Hg from 
age 11 to 17  years.  
 
 IAR17) 
Re
actions harmful to the living body that are caused by [CONTACT_434120] , 
occurring during or within 24  hours after completion of the infusion ( e.g., chill, fever, a 
feeling of body temperature fluctuation, nausea, high blood pressure).  
 
Also, in addition to reported S AEs, all the events that have significantly abnormal laboratory 
values or require such action as the discontinuation, temporary cessation, or addition of 
important combination therapy with respect to the investigational product should be evaluated 
as significant AEs. 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 39 / [ADDRESS_550190] randomized 
to one of the 2 treatment groups (2.0 or 4.0  mg/kg/week JR-171 group) will stay at hospi[INVESTIGATOR_434087] [ADDRESS_550191] the venous blood sample.  
In the eCRF, whether or not a measurement has been performed and, if applicable, the sample 
collection date and time should be recorded. For the reporting of results, data should be 
reported by [CONTACT_25699].  
Rationale for the Pharmacokinetics Assessments  
The PK endpoints were selected to determine the PKs of and exposure to JR-171 after 
continuous intravenous infusion in patients with MPS I by [CONTACT_434121]. In a nonclinical PK study in cynomolgus monkeys, measured plasma 
JR-171 concentrations showed that the plasma exposure to JR-171 up to 24  hours after the 
start of administration (AUC 0-24) accounted for almost 100% of the plasma exposure from the 
start of administration to infinity (AUC 0-∞). It was therefore decided to measure drug 
concentration up to 21  hours after the end of administration (the last blood sampling time point) 
in order to calculate PK parameters.  
8.[ADDRESS_550192] with the sponsor.  
Care is to be taken not to contaminate the sample with blood, heparin or heparin-like 
compounds when collecting samples. In the eCRF, whether or not a measurement has been 
performed as well as the sample collection date, if performed, should be recorded. For the 
reporting of results, the measurement results should be reported by [CONTACT_25699].  
Subjects will undergo lumbar puncture under sedation or general anesthesia to obtain CSF. 
Fluoroscopy with anesthesia may be needed in subjects with difficult access to CSF.  
To minimize the risks associated with lumbar puncture procedures in the subjects with MPS I, 
the principal investigator [INVESTIGATOR_434088]:  
- Intravenous or oral administration of sedatives prior to the procedure should be considered 
when subject’s discomfort, anxiety or agitations are such that they affect the safe and smooth 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 40 / [ADDRESS_550193] before administration of JR-171 or laronidase 
to measure serum HS and DS concentrations. Care is to be taken not to contaminate the 
sample with heparin or heparin-like compounds when collecting samples. In the eCRF, whether 
or not a measurement has been performed and, if applicable, the sample collection date should 
be recorded. The measurement results should be reported by [CONTACT_25699].  
Rationale for this Exploratory Assessment  
Given systemic accumulation of HS and DS in patients with MPS I, this assessment was 
selected to explore the efficacy of JR-171 on systemic symptoms.  
8.5.6 Liver and Spleen Volumes  
Computed tomography (CT) or magnetic resonance imaging (MRI) will be performed before 
administration of JR-171 or laronidase to measure liver and spleen volumes. The same 
modality (CT or MRI) should be used throughout the study for the same subject. When 
selecting CT or MRI, the principal investigator [INVESTIGATOR_434089]’s condition, treatment status or radiation exposure doses, including conduct of other 
imaging tests in order to protect the subject’s safety. In the eCRF, whether or not a 
measurement has been performed as well as the date and results of measurement should be 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 42 / 68 
 HVLT-R, refer to the separate sponsor manual.  
Rationale for this Exploratory Assessment  
The BVMT-R will be used to measure the visuospatial memory, and the HVLT-R will be used 
to assess the verbal learning and memory.  
8.5.11 T.O.V.A.  
The T.O.V. A., version 9 (T.O.V.A.) (visual test) will be measured in Part 2, and will be performed 
only in subjects at least [ADDRESS_550194] version will be tested in Part 2, and will be performed only for 
subjects accompanied by [CONTACT_434118], caregiver or equivalent thereof. The PedsQL-FIM will be 
performed to assess specifically caregiver’s and family’s burden. In the eCRF, whether or not 
a test has been performed as well as the date and results of the test should be recorded.  
 
Rationale for this Exploratory Assessment  
This assessment was selected to explore how the QoL has changed, because it is known that 
burden of caregiver and family of patients with MPS I is high and gathering data of QoL is 
important.  
8.5.13 Status of Cross-Reactive Immunologic Material (CRIM)  
A blood specimen and fibroblasts will be collected once in the JR-171-[ADDRESS_550195] is the mean change from baseline. The null 
hypothesis for comparison (H 0) with threshold value of delta ( Δ) and the alternative hypothesis 
of effect of JR-171 ( H1) are defined as follow, where μ denotes mean change from baseline in 
HS or DS concentrations in CSF and Δ = 0. 
H0: μ = Δ  
H1: μ > Δ or μ < Δ . 
 
No hypothesis testing is planned for the other exploratory endpoints, safety and PK 
assessments.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 43 / 68 
 9.2 Sample Size Determination  
Part 1 : 4 subjects ( 18 years or older)  
Part 2 : Approximately [ADDRESS_550196]- in-human study of JR-171, adult patients (18  years old or older) with mild MPS I 
who can report their own subjective symptoms are deemed appropriate to confirm the safety 
of JR-[ADDRESS_550197] the birth 
prevalence of approximately 0.11 to 3.62 per 100000 live births.2) In addition, 60.9% of the 
pa
tients are reported to have severe disease manifestations with intellectual disability,3) 
in
dicating that there may be very few adult patients with mild MPS I who have little or no 
intellectual disability. Based on these considerations and the target sample size of 4 subjects 
was selected for Part 1 in view of feasibility.  
 
In Part 2, pediatric patients will be able to participate since treatment of MPS I often starts in 
childhood. It is assumed that only a small number of patients could undergo lumbar puncture. 
Furthermore, it is reported that 54.9% of severe MPS I patients have a history of HSCT.8) 
The
refore, it is assumed only a very limited number of patients would be eligible to participate 
in the study. Based on these considerations and in view of feasibility, the target sample size of 
approximately 15 subjects was selected to evaluate the safety and efficacy of JR-171.  
9.3 Populations for Analyses  
The following populations are defined:  
 
Population  Description  
Safety set (SS)  All subjects who sign the ICF.  
Pharmacokinetic set (PKS)  Subjects assigned to study intervention and have 
da
ta for plasma drug concentration after 
administration of JR- 171. 
Full analysis set (FAS)  Subjects assigned to study intervention and have 
da
ta for at least one exploratory endpoint after 
administration of JR- [ADDRESS_550198] 
important endpoints including primary and key secondary endpoints.  
9.4.1 General Considerations  
[IP_ADDRESS] Significance Level and Confidence Interval  
Unless otherwise specified, all statistical tests will be 2-sided hypothesis tests performed at 
the 5% level of significance and all confidence intervals will be 2-sided 95% confidence 
intervals. All statistical tests and confidence intervals will be parametric assuming normally 
distributed sample means.  
[IP_ADDRESS] Definitions of Baseline  
Unless otherwise specified, the baseline value will be defined as the measurement prior to and 
closest to the date of the first dose of JR-171.  
[IP_ADDRESS] Definitions of Study Period 
Data for regular scheduled visits will be summarized as below.  
 
JR-171 Phase I/II study  Ver sion 6.00  
Protocol number: JR-171-101   12 November 2021  
 45 / [ADDRESS_550199] to the presence or absence of 
antibody development at each time point.  
9.4.4 Analysis of the Pharmacokinetic endpoints  
This section outlines the planned analyses of the PK endpoints of the JR-171-101 study.  
PK analyses will be performed on the PKS.  
 
Part 1  
For the plasma drug concentration at each time point, summary statistics, geometric mean, 
and geometric coefficient of variation (CV) will be calculated for each dose. In addition, time 
courses of mean and standard deviation ( SD) will be created for each dose, and a listing and 
time courses will be created for each subject.  
The following PK parameters will be calculated for each subject using a non-compartment 
model analysis, and summary statistics, geometric mean, and geometric CV will be calculated 
for each dose. In estimating the parameters, the plasma drug concentration calculated by [CONTACT_434122], and the actual blood collection time will be used.  
 
Part [ADDRESS_550200] using a non-compartment 
model analysis, and summary statistics, geometric mean, and geometric CV will be calculated 
for each group. In estimating the parameters, the plasma drug concentration will be calculated 
using the plasma drug concentration at baseline, and the actual blood collection time will be 
used.  
 
[PK Parameters]  
 AUC 0-t 
 Cmax 
 AUC 0-∞ 
 tmax 
 kel 
 t1/2 
 MRT 0-t 
9.4.5 Analyses of the Exploratory Endpoints  
The following section outlines the planned analyses of the exploratory endpoints of the 
JR-171-101 study. Analyses will be performed on the FAS, unless otherwise specified.  
[IP_ADDRESS] Drug Concentration in CSF  
For drug concentration in CSF, summary statistics of measured values will be calculated by 
[CONTACT_434123] (2.0 or 4.0  mg/kg).  
[IP_ADDRESS] HS and DS Concentrations in CSF  
For HS and DS concentrations in CSF, summary statistics of measured values at each time 
point will be calculated, and time courses will be created for Part 1 and each group in Part  2. 
In addition, difference from baseline, ratio to baseline and relative change from baseline at 
Week  4 in Part  1 or Week  12 in Part  2 and corresponding 2-sided 95% confidence interval will 
be calculated.  

JR-171 Phase I/II study  Ver sion 6.00  
Protocol number: JR-171-101   12 November 2021  
 47 / 68 
 . 
9.5 Interim Analyses  
No interim analyses will be performed in the JR-171-101 study.  
9.6 Independent Data Safety Monitoring Committee (IDSMC)  
For the purpose of consistent and objective safety assessment, the sponsor will establish an 
IDSMC completely independent from the sponsor.  
The sponsor will immediately set up the IDSMC. The IDSMC will evaluate safety and report 
the results to the sponsor.  
Detailed procedures for the IDSMC are provided in the Safety Evaluation Manual which is 
created by [CONTACT_3174] a separate document.  

JR-171 Phase I/II study Ver sion 6.00
Protocol number: JR-171-101 12 November 2021
48 / 6810. Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Regulatory and Ethical Considerations
The study will be conducted in accordance with the guidelines in ICH-GCP, the 18th World 
Medical Association’s Declaration of Helsinki, applicable regulatory/regional requirements and 
this protocol.
The appropriate IRB/IEC must approve the protocol, patient information sheet and informed 
consent document, and where appropriate, agree to monitor the conduct of the study and 
agree to review periodically. The principal investigator [INVESTIGATOR_434090]/IEC has approved the study before the study may begin.
In addition, the principal investigator [INVESTIGATOR_434091]/IEC approval of 
any revisions to the patient information sheet and informed consent document or amendments 
to the protocol.
Details of the IRB/IEC’s composition including names of their members, their qualifications and 
what function they perform in the committee ( e.g., chairman, specialist, lay-member) will be 
made available to conform to regulations governing the conduct of clinical studies within each 
country. The constitution of the IRB/IEC must be supplied to the sponsor.
10.1.[ADDRESS_550201] Investigator’s Brochure, and agree on the content and compliance with 
the protocol. The principal investigator [INVESTIGATOR_434092].
Protocol Deviations or Changes
The principal investigator [INVESTIGATOR_434093] a deviation from or change to the 
protocol without obtaining prior written agreement from the sponsor and a review-based written 
approval from the IRB/IEC in advance (except in medically unavoidable circumstances such 
as to avoid the immediate danger to a subject, or cases in which changes are related only to 
the administrative matters of the clinical study).
In medically unavoidable circumstances, such as avoiding an immediate danger to a subject, 
the principal investigator [INVESTIGATOR_50291], as promptly as possible, the details of and reasons for 
deviations or changes to the sponsor, as well as to the head o f medical institution (in countries 
where applicable) and to the IRB/IEC of the study institution to obtain approval for such 
deviations or changes. In addition, the principal investigator [INVESTIGATOR_879], without delay, a report 
of any change of the clinical study that can have a significant impact on the conduct of the 
clinical study or increase a danger to a subject, to the sponsor as well as to the head of medical 
institution (in countries where applicable) and to the IRB/IEC of the study institution.
Note that the principal investigator [INVESTIGATOR_434094].
Of all the deviations from the protocol, the sponsor will define the five items below as critical 
deviations and will collect and evaluate information regarding them.
1.A deviation in which a subject had been enrolled in the clinical study without meeting the
entry criteria
2.A deviation in which a subject fell under the discontinuation criteria during the clinical study
period but had not been withdrawn
3.A deviation in which a subject violated the assigned dosage (administration requirements)
4.A deviation in which a subject received a concomitant medication/therapy that is prohibited
5.Other critical deviations
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 49 / [ADDRESS_550202] Investigator’s Brochure.  
Based on the revised protocol and the latest Investigator’s Brochure, the principal investigator 
[INVESTIGATOR_434095]. The principal investigator [INVESTIGATOR_434096].  
Submit the revised protocol to the head of the medical institution (in countries where 
applicable).  
In addition, when changes are made in administrative matters, etc. that are not related to the 
nature of the clinical trial plan, the revised edition should be reported to the principal 
investigator [INVESTIGATOR_399242] (in countries where applicable) at any time.  
10.1.[ADDRESS_550203] to any liability directly or indirectly caused by [CONTACT_434124], the sponsor assumes liability by [CONTACT_434125](s) and his/her assistants, only in cases that meet all of the following; the principal 
investigator(s) and his/her assistants have followed the instructions of the sponsor in 
accordance with this protocol and any amendments; the investigational products administered 
to the subject in this clinical trial have been supplied by [CONTACT_456]; the principal investigator 
[INVESTIGATOR_43865]/her assistants have performed this clinical study in accordance with current medical 
and scientific practice. 
A letter of indemnity will be signed between the sponsor and the principal investigator(s) 
(between the sponsor and the head of the medical institution in countries where applicable) , 
and the sponsor will insure according to local requirements.  
Compensation for health damages  
When the causal relationship between the JR-[ADDRESS_550204]  
In the event of study-related health damage, the patient’s out- of-pocket expenses excluding 
benefits from health insurance, etc. shall be reimbursed by [CONTACT_456].  
Compensation claim 
In the event that a request for compensation from a subject has been filed or a matter subject 
to compensation is suspected, the participating medical organization should immediately 
contact [CONTACT_456]. The sponsor will respond promptly in accordance with the SOP for health 
damage compensation for test subjects in-house.  
Insurance  
The sponsor will purchase insurance to ensure the performance of these procedures.  
10.1.4 Financial Disclosure  
Principal investigators and subinvestigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Principal investigators are responsible for providing information on financial interests during 
the course of the study and for one year after completion of the study.  
10.1.5 Audit  
Authorized representatives of the sponsor and/or a national regulatory authority may visit the 
center to perform audits or inspections, including source data verification. The purpose of a 
the sponsor audit or inspection is to systematically and independently examine all study related 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 50 / [ADDRESS_550205] access to all trial related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 
inspection by [CONTACT_3482].  
10.1.[ADDRESS_550206], “authorized 
representative signature [CONTACT_124359]”, of all individuals involved in the study (medical, nursing and 
other staff). In collaboration with the sponsor, the principal investigator [INVESTIGATOR_434097]/or study procedures is given to all of these staff, 
and that any new information of relevance to the performance of the JR-171-101 study is 
forwarded to the staff involved.  
10.1.7 Informed Consent Process  
The principal investigator [INVESTIGATOR_434098]/IEC for approval of the ICF for the 
patients and written permission form for patient’s legally acceptable representative as well as 
written information for them modified from the master sponsor ICF to comply with each 
country’s applicable regulations.  
 
The ICF and written information should include explanations of the elements as described i n 
points 1 to 21 below:  
1. That the study involves research;  
2. The purpose of the study;  
3. Principal investigator’s name, job title and contact [CONTACT_3031];  
4. Methods of study (including the experimental aspects of the study, subject inclusion criteria, 
and the probability for random assignment (if applicable) to each treatment);  
5. The reasonably expected clinical benefits and risks or inconveniences (When there is no 
intended clinical benefit to the subject, the subject should be made aware of this);  
6. If a patient is to be a subject, whether or not there is any alternative procedure(s) or 
course(s) of treatment that may be available to the patient, and their important potential 
benefits and risks;  
7. The expected duration of the subject’s participation in the study;  
8. That the subject’s participation in the study is voluntary and that the patient or the subject’ s 
legally acceptable representative may refuse to participate or withdraw from the study, at 
any point of time, without penalty or loss of benefits to which the subject is otherwise 
entitled if not participating in the study;  
9. That the monitor(s), the auditor(s), the IRBs, and the regulatory authority(ies) will be able 
to access the subject’s original medical records, without violating the confidentiality of the 
subject, and that, by [CONTACT_2960] a written ICF, the patient or the subject’s legally acceptable 
representative is authorizing such access;  
10. That the subject’s identity will remain confidential even if the results of the study are 
published;  
11. The point of contact [CONTACT_434126], or make a contact [CONTACT_4490], 
for further information regarding the study and the rights of study subjects, and in the event 
of study-related injury;  
12. The compensation and treatment available to the subject in the event of study-related 
injury;  
13. The number of subjects to be involved in the study;  
14. That the subject or the subject’s legally acceptable representative will be informed as soon 
as possible if information becomes available that may be relevant to the subject’ s 
willingness to continue participation in the study;  
15. The circumstances or reasons under which the subject’s participation in the study may be 
terminated;  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 51 / [ADDRESS_550207] for participating in the study;  
17. Details of reimbursement to be made to the subject for participating in the study 
(agreements on how the amount is determined, etc.);  
18. The rules the subject should comply with;  
19. The type of the IRB that examines or discusses whether or not the study is appropriate, 
matters that are to be examined or discussed by [CONTACT_434127], and other matters 
associated with IRBs that directly concern the study (including the name [CONTACT_434140], and information concerning 
such an organizer that is available to view);  
20. That the written SOP for the IRB is made available to view by [CONTACT_434128], etc. and that the subject should come forward if he/she 
wishes to view these documents;  
21. That the data used in applying for an approval may be used by [CONTACT_434129].  
 
The principal investigator [INVESTIGATOR_434099]. In the case of a patient who is under the age of 18 (20  years i n 
Japan) at the time of informed consent process, or if it is not possible to obtain consent from 
the patient him/herself due to his/her intellectual disabilities associated with MPS I, the 
principal investigator [INVESTIGATOR_434100]’ s 
legally acceptable representative and written consent should be obtained from the patient 
him/herself too, wherever possible.  
The principal investigator [INVESTIGATOR_434101], purpose, possible risks and 
benefits of the study. Patients must also be notified that they are free to discontinue from the 
study at any point in time. The patient should be given the opportunity to ask questions and be 
allowed time to consider the information provided.  
The patient’s signed and dated informed consent must be obtained before conducting any 
procedure specifically for the study. The signed and dated ICFs will be kept by [CONTACT_1961] [INVESTIGATOR_434102]. A copy of 
the signed written ICF must be given to the patient.  
The global ICF will be approved by [CONTACT_434130]; the new version has to be approved by [CONTACT_434131]/IECs.  
The written ICF will explain that the study data will remain confidential in accordance with 
national data legislation. The subject ID code will only identify subjects in the database. The 
written ICF will also explain that for data verification purposes, authorized representatives of 
the sponsor, regulatory authority, and IRB/IEC require direct access to parts of the hospi[INVESTIGATOR_428949], including the subject’s medical history.  
The ICF may need to be revised during the study, should important new information become 
available that may be relevant to the safety of the subject. In this instance, the IRB/IEC should 
always give approval; if applicable, existing subjects should be informed of the changes, and 
signed consent obtained for the new changes.  
The principal investigator [INVESTIGATOR_347160], with the consent of the subject, inform the subject’s primary 
physician about their participation in the clinical study.  
As used in this protocol, the term “informed consent ” includes all consent given by [CONTACT_434132].  
10.1.8 Blood and CSF Volume  
Blood and CSF volumes that will be collected in this study are described below. Additonal 
testing that accompanies blood sampling will be performed as deemed necessary by [CONTACT_28824] [INVESTIGATOR_249585].  
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 53 / 68 
 review by [CONTACT_1201]/IEC as to whether continuing the clinical study is appropriate, according to 
each institution’s SOP.  
1. When the sponsor notifies the principal investigator [INVESTIGATOR_434103], including safety 
information (when the sponsor notifies the study Institution Head of new information in 
countries where applicable).  
2. When the principal investigator [INVESTIGATOR_434104] a S AE (when the 
principal investigator [INVESTIGATOR_434105] a SAE in countries where applicable).  
3. When the principal investigator [INVESTIGATOR_434106] (when the principal investigator [INVESTIGATOR_434107]).  
10.1.[ADDRESS_550208] of the study is in compliance with the currently 
approved protocol/amendment(s), with ICH-GCP, and with applicable regulatory 
requirement(s).  
 
Before the study begins, a monitor representing the sponsor will visit the investigational site to 
determine the adequacy of the facilities and to discuss with the principal investigator(s) and 
other personnel involved in the study their responsibilities with regard to protocol adherence, 
and the responsibilities of the sponsor or its representatives.  
During the study, a monitor representing the sponsor will have regular contact [CONTACT_434133], including visits to:  
 provide information and support to the principal investigator(s)  
 confirm that facilities remain acceptable  
 confirm that the investigational team is adhering to the protocol  
 confirm that data are being accurately recorded in the eCRF  
 confirm that the study is conducted according to the ICH-GCP  
 confirm that an update of the screening log is performed, and that investigational 
product accountability checks are being performed  
 Perform source data verification (a comparison of the data in the eCRFs with the 
subject’s records at the hospi[INVESTIGATOR_7117], and other records relevant to the study.)  
This will require direct access to all original records for each subject ( e.g., clinic charts).  
The monitor, medical monitor or the sponsor representatives will be available between visits if 
the principal investigator(s) or other staff at the investigational site need information and advice.  
10.1.[ADDRESS_550209] audits that are performed by a controller of audit/auditor, who is 
independent of the department involved in the clinical study, in the company and the study 
institution or an outsourcing contractor as needed, according to the SOP that are defined 
separately.  
 
At the request of a monitor, controller of audit/auditor, the IRB/IEC, or the regulatory authority, 
the principal investigator/the study institution head will provide direct access to all the records 
related to the clinical study, including source documents.  
10.1.15 Data Collection and Management Responsibilities  
The management of data and each specific data point will be determined before data are 
locked, through discussion(s) with medical specialists and statisticians, as needed.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 54 / 68 
 Data collection is the responsibility of the clinical study staff at the site under the supervision 
of the principal investigator. The principal investigator [INVESTIGATOR_19760], 
completeness, legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate 
recording of data in the eCRF.  
Data recorded in the eCRF derived from source documents should be consistent with the data 
recorded on the source documents.  
Clinical data (including AEs and concomitant medications) will be entered into an eCRF, a 
[ADDRESS_550210] 
protection and internal quality checks to identify data that appear to be inconsistent, incomplete, 
or inaccurate. Clinical data will be entered directly into the eCRF from the source documents.  
For completion/correction of the eCRF, refer to the separate sponsor manual.  
10.1.[ADDRESS_550211]’s medical records will be 
verified carefully by [CONTACT_434134]-up. The sponsor provides 
project oversight at all times. A project representative from the sponsor will be available to the 
study sites by [CONTACT_18623]/or by [CONTACT_765].  
The principal investigator [INVESTIGATOR_434108]. The eCRF forms will be monitored by [CONTACT_434135] [INVESTIGATOR_434109]. Data lists will 
be generated from the database enabling a direct comparison between the original case report 
forms and the database. This will facilitate the clarification of any errors. These corrected 
documents, and other study documents, will be retained as the final study documentation.  
The principal investigator [INVESTIGATOR_434110] ( i.e., 
hospi[INVESTIGATOR_307]/unit code, study ID code and study number) for as long as the sponsor requests after 
completion or discontinuation of the clinical study. Other source documents, such as subject 
files and clinic case notes, must be retained for the maximum period of time permitted by [CONTACT_86677][INVESTIGATOR_307], institution or private practice and if this is less than the sponsor requires after the 
completion or discontinuation of the clinical study, then the sponsor must be notified to arrange 
record retention.  
If the principal investigator [INVESTIGATOR_222979], or otherwise withdraws his/her responsibility for 
maintaining the study documentation, the sponsor must be notified in writing so that adequate 
provision can be made with regard to the ID codes of subjects, copi[INVESTIGATOR_434111] ( e.g., copi[INVESTIGATOR_1495]) and other source data (if available). This responsibility 
may be transferred to the sponsor, who will make arrangements to store the data. An inventory 
of stored data will be held by [CONTACT_458] [INVESTIGATOR_1238] a copy by [CONTACT_456].  
Data without a written or electronic record will be identified before study start and should be 
recorded directly on the eCRF, which will be documented clearly as being the source data.  
10.1.17 Storage of Records and Other Documents  
The principal investigator/institute shall store the essential documents and records related to 
the clinical trial for either of the following periods, [ADDRESS_550212] approval of a marketing application in an ICH region and until there are no pending 
or contemplated marketing applications in an ICH region. These documents should be 
retained for a longer period however if required by [CONTACT_8146](s) 
or if needed by [CONTACT_456].  
2. If the sponsor discontinues the clinical development of an investigational product ( i.e., for 
any or all indications, routes of administration, or dosage forms), the sponsor should 
maintain all sponsor-specific essential documents for at least 2  years after formal 
discontinuation or in conformance with the applicable regulatory requirement(s).  
Principal investigators/institutes take measures to ensure that these records are stored 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 55 / [ADDRESS_550213] been collected and a study-site closure visit has been performed by [CONTACT_456].  
The principal investigator [INVESTIGATOR_434112]-site closure at any time, provided there is 
reasonable cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_434136] [INVESTIGATOR_434113]:  
 Failure of the principal investigator [INVESTIGATOR_434114], the requirements of 
the IRB/IEC or local health authorities, the sponsor’s procedures, or ICH-GCP 
guidelines  
 Inadequate recruitment of subjects by [CONTACT_458]  
 Discontinuation of further study intervention development  
 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
Principal Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by 
[CONTACT_1214]. The principal investigator [INVESTIGATOR_434115]/or follow- up. 
10.1.[ADDRESS_550214] that is appropriate to their participation 
in the study.  
10.1.21 Additional considerations  
It is not applicable for the JR-171-101 study.  
 
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 67 / 68 
 11. References  
1) Munoz-Rojas MV, Shaukat AK, Giugliani R. Mucopolysaccharidoses Update (2 Volume 
Set), Mucopolysaccharidosis type I: Clinical features, biochemistry, diagnosis, genetics, 
and treatment. Nova science publishers. 2018; Chapter 9: p. 143- 64. 
2) Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. 
Epi[INVESTIGATOR_434116]. Mol Genet Metab. 2017; 121(3): 227-40.  
3) Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history 
of MPS I: global perspectives from the MPS I Registry. Genetics in Medicine. 2014; 
16(10): 759-65.  
4) Muenzer J, Wraith JE, Clarke LA, and the International Consensus Panel on 
Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: 
management and treatment guidelines. Pediatrics. 2009; 123(1): 19-29.  
5) de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme 
replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in 
patients with mucopolysaccharidosis type I: results of a European consensus procedure. 
Orphanet J Rare Dis. 2011; 6(55).  
6) Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, et al. Outcomes of 
transplantation using various hematopoietic cell sources in children with Hurler 
syndrome after myeloablative conditioning. Blood. 2013; 121(19): 3981-87.  
7) Aldurazyme (Generic Name: [CONTACT_434141]), HIGHLIGHTS OF PRESCRIBING 
INFORMATION. Revised April 2013.  
8) D'Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and 
treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. 
European Journal of Pediatrics. 2012; 171(6): 9 11-9. 
9) Forni G, Malvagia S, Funghini S, Scolamiero E, Mura M, Della Bona M, et al. LC-MS/MS 
method for simultaneous quantification of heparan sulfate and dermatan sulfate in urine 
by [CONTACT_434137]. Clin Chim Acta. 2019; 488: 98-103.  
10) Giugliani R, Giugliani L, de Oliveira Poswar F, Donis KC, Corte AD, Schmidt M, et al. 
Neurocognitive and somatic stabilization in pediatric patients with severe 
Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin 
receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-
2 trial. Orphanet Journal of Rare Diseases 2018; 13(1).  
11) Suominen P, Virtanen A, Lehtonen-Veromaa M, Heinonen OJ, Salmi TT, Alanen M, et 
al., Regression-based reference limits for serum transferrin receptor in children 6 
months to 16 years of age. Clin Chem. 2001; 47(5): 935- 7. 
12) Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-
replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001; 344(3): 182- 8. 
13) National institutes for Quantum and Radiological Science and Technology [Internet]. 
Available from: https://www.qst.go.jp/site/qms/1889.html (Japanese) and 
https://www.innervision.co.jp/01inner/2010/201006bougo/046-049.pdf (Japanese)  
14) Smith-Bindman R, Wang Y , Chu P , Chung R, Einstein AJ, Balcombe J, et al. International 
variation in radiation dose for computed tomography examinations: prospective cohort 
study. BMJ. 2019; 364.  
15) Japan Radiological Society, Japanese Society of Radiological Technology and 
Japanese Society of Pediatric Radiology. Pediatric CT guideline.(Japanese) 2005.  
16) Sampson HA, Muñoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al. 
S
ymposium on the definition and management of anaphylaxis: summary report. J 
Allergy Clin Immunol. 2005 ; 115(3): 584-91.  
JR-171 Phase I/II study  Ve rsion 6.00  
Protocol number: JR-171-101   12 November 2021  
 68 / 68 
 17) Doessegger L, Banholzer ML. Clinical development methodology for infusion-related 
reactions with monoclonal antibodies. Clin Transl Immunolo gy. 2015; 4(7):e39.  
 
 